CTIS.eu › Cities › Italy › Rome
Rome
Italy
2,096 total trials
907 recruiting
Filter these 2,096 trials by phase, condition, sponsor and more.
Open in Search →
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.
2024-515470-26-00
4
2024-10-31
Relapsing Remitting Multiple Sclerosis
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
2023-509560-16-00
5
2024-10-29
Juvenile psoriatic arthritis (jPsA)
2023-506632-32-00
5
2024-10-28
Metastatic colorectal cancer
2024-511453-22-00
1
2024-10-28
Participants with Advanced Solid Malignancies
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
2023-509851-15-00
5
2024-10-22
Colon cancer
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
2024-516088-10-00
4
2024-10-16
Pulmonary Tuberculosis
2023-509428-16-00
10
2024-10-15
HIV-1 Infection
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
2023-506686-66-01
10
2024-10-09
HLA-A2 negative metastatic uveal melanoma
2023-508581-15-00
5
2024-10-08
Heart condition
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
2023-504733-53-00
4
2024-09-26
Cushing's Disease
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
2024-510954-28-01
4
2024-09-23
grade 1, 2 and 3 meningioma
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
Showing 817–840 of 2,096 trials